Outcome in elderly acute myeloid leukaemia

Irish Medical Journal

Volumn 101, Issue 10, 2008, Pages

  Osman, H ^a   Murray, M ^a   Egan, E ^a   ODwyer, M ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CYTOGENETICS; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTOGENETICS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61549107986     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bincker H. Population-based age and sex specific incidence rates in the main types of leukemia. Scand J Haematol 1989;29:241.
2. Cassileteth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79:1924.
3. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994;331:896.
4. Mitus JA, Miller KB, Schenkein DP, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995;13:560.
5. Champlin RE, Gajewski JL, Golde DW. Treatment of acute myelogenous leukemia en the elderly. Semin Oncol 1989;16:51.
6. Löwenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-1274.
7. Staib P, Lathan B, Knoppel-Schwark S, et al. Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients. Ann Oncol 1998;9:221-223.
8. Baudard M, Beauchamp-Nicoud A, Delmer A, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia 1999; 13, 1481-1490.
9. Goldstone A, Burnett A, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
10. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
11. Grinwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. Blood 1998;92:2322.
12. Ries LAG, Melbert D, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
13. Fröhling S, Schlenk R, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trialAMLHD98-B. Blood, 2006;108: 3280-3288.
14. Appelbaum F, Gundacker H, Head D, et al. Age and acute myeloid leukemia. Blood, 2006; 107: 3481-3485.
15. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 2001; 98:1312-1320.
16. G. Öberg1, A. Killander, M. Björeman, et al. Long-term follow-up of patients = 60 yr old with acute myeloid leukaemia treated with intensive chemotherapy. Eur J Haematol 2002; 68: 376-381.
17. Burnett A, Russell N, Kell J, Milligan D and Culligan D. A Phase 2 Evaluation of Single Agent Clofarabine as First Line Treatment for Older Patients with AML Who Are Not Considered Fit for Intensive Chemotherapy. Blood (ASH annual meeting abstracts) 2004 104: Abstract 869.
18. Burnett A, Baccarani M, Johnson P, et al. A Phase II Study (Biov-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable. Blood (ASH annual meeting abstracts) 2006, 108: Abstract 425.
19. Burnett A, Kell W, Hills R, et al. The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study. Blood (ASH annual meeting abstracts), Nov 2006; 108: 1950.